Clinical Characteristics and Outcomes of Patients With Chronic Digoxin Toxicity Presenting to the Emergency Department
Open Access
- 28 September 2026
- journal article
- Published by Gaziantep Islam Science and Technology University in Experimental and Applied Medical Science
- Vol. 7 (3) , 193-204
Abstract
Purpose: Digoxin is widely used to treat heart failure and atrial fibrillation but has a narrow therapeutic index, making elderly patients particularly susceptible to chronic toxicity. Because its clinical manifestations are often nonspecific, diagnosis in the emergency department (ED) may be delayed. To evaluate the demographic characteristics, clinical presentation, electrocardiographic findings, laboratory parameters, and in-hospital outcomes of patients presenting to the ED with chronic digoxin toxicity.Methods: This retrospective cohort study included adult patients admitted to a tertiary-care ED over a five-year period who received chronic digoxin therapy and had serum digoxin levels ≥2,0 ng/mL. Patients with acute intentional overdose or incomplete medical records were excluded. Demographic characteristics, comorbidities, presenting symptoms, Electrocardiogram (ECG) findings, laboratory results, and in-hospital outcomes were analyzed.Results: A total of 188 patients were included (mean age 73,50±12,10 years; 42,00% male). Dyspnea (35,10%), chest pain (23,40%), and nausea/vomiting (22,90%) were the most common presenting symptoms. Heart failure (76,60%) and hypertension (71,30%) were the most frequent comorbidities. Valvular heart disease was more common in patients aged ≤ 65 years (p=0,005), whereas serum sodium levels were higher in older patients (r=0,282, p<0,001). Serum digoxin levels correlated positively with potassium, urea, creatinine, creatine kinase–myocardial band (CK-MB), and troponin, and negatively with hemoglobin. Higher digoxin concentrations were associated with increased in-hospital mortality (p=0,006).Conclusion: Chronic digoxin toxicity is an important and frequently under-recognized condition in the ED. Early recognition based on clinical, laboratory, and ECG findings may improve patient outcomes.Keywords
Funding Information
- None (196)
This publication has 15 references indexed in Scilit:
- 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureEuropean Heart Journal, 2023
- Digoxin use in contemporary heart failure with reduced ejection fraction: an analysis from the Swedish Heart Failure RegistryEuropean Heart Journal - Cardiovascular Pharmacotherapy, 2021
- Digoxin Use and Outcomes in Patients With Heart Failure With Reduced Ejection FractionThe American Journal of Medicine, 2019
- Use of prescription drugs in the older adult population—a nationwide pharmacoepidemiological studyEuropean Journal of Clinical Pharmacology, 2019
- Digoxin: The good and the badTrends in Cardiovascular Medicine, 2016
- Digoxin-associated mortality: a systematic review and meta-analysis of the literatureEuropean Heart Journal, 2015
- Cardiac Glycoside ToxicityCritical Care Clinics, 2012
- Relationship of Serum Digoxin Concentration to Mortality and Morbidity in Women in the Digitalis Investigation Group TrialJACC, 2005
- Age‐related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applicationsBritish Journal of Clinical Pharmacology, 2003
- Sex-Based Differences in the Effect of Digoxin for the Treatment of Heart FailureNew England Journal of Medicine, 2002